openPR Logo
Press release

Klebsiella Pneumoniae Infections Treatment Market with Current Trends Analysis, 2014 – 2020

07-19-2018 11:27 AM CET | Health & Medicine

Press release from: Transparency Market Research

Klebsiella Pneumoniae Infections Treatment Market with

Klebsiella pneumoniae infections are usually hospital acquired and patients with compromised defense mechanisms are more prone to these infections. Klebsiella pneumoniae is a pathogenic strain of genus Klebsiella of Enterobacteriaceae and is present in the normal flora of the respiratory, intestinal, and urinogenital tracts of humans. Although this bacteria is essential for normal bowel health and functioning, serious infection occurs when it gets outside the gut.

According to the Centers for Disease Control and Prevention (CDC), more than 2 million patients suffer from nosocomial infections annually out of which 100,000 people die. Klebsiella pneumonia contributes to 8% of overall nosocomial infections. Normal pneumonia can be resolved effectively with medications, but Klebsiella pneumonia causes lung destruction and abscesses in many cases resulting into higher mortality rate. In Klebsiella pneumonia, the mortality rate is above 50% which increases to 90% in cases which remain untreated.

Obtain Report Details @ https://www.transparencymarketresearch.com/klebsiella-pneumoniae-infections-treatment.html

Cephalosporins are among the most widely used class of drugs for treating Klebsiella infections and are often prescribed as monotherapy or in conjunction with aminoglycosides. Some of the prominent antibiotics found to be active against Klebsiella pneumoniae include moxifloxacin, ofloxacin, levofloxacin, ceftriaxone, betamethasone, cefepime, meropenem, terizidone, cefixime, tobramycin, and gemifloxacin. Today, several antibiotics are used to treat numerous infectious diseases caused by pathogenic microbes. However, many such medicines are becoming ineffective as the pathogenic microorganisms are becoming resistant to evolve themselves into multi drug resistant (MDR) strains.

The strains of Klebsiella pneumoniae which produce Klebsiella pneumoniae carbapenemases (KPCs) are increasingly becoming common and are capable of hydrolyzing broad spectrum beta-lactam antibiotics including penicillings, and carbapenams. Klebsiella species can easily become resistant to carbapenems and unfortunately these are the only last resort antibiotics against gram-negative Klebsiella pneumonia. At present, tigecycline and polymixins (particularly polymixin B) are the only useful drugs in treating KPC producing bacteria. There is a great need of medicines which can treat the infectious strains of Klebsiella genus.

Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2859

Widespread research activities are underway to find out better therapy for Klebsiella pneumonia infections, however only modest success has been achieved until date. A few promising drugs and treatment procedures are expected to bring paradigm shift in the treatment of Klebsiella pneumonia infections. Some of the drugs in various stages of drug development include CB-618, RX-04, CB-027, SM-295291, SM-369926, SGX-942, NAB-741, NAB-7061, IBN-1, and PMBN-fMLF.

In a recent development in the market, Tetraphase Pharmaceuticals, Inc. was awarded with USD 67 million for development of its pipeline drug TP-434. This clinical stage drugs is a potent antibiotic against multi drug resistant (MDR) gram negative microorganism and can provide effective treatment in Klebsiella pneumoniae infection. Earlier in 2011, Rib-X Pharmaceuticals, Inc. and Sanofi S.A. had signed an exclusive worldwide agreement for research collaboration on RX-04 development program. This program is aimed at breaking ground in antibiotic discovery through developing new class of antibiotics for treating MDR pathogenic infections. Such kind of ongoing research activities by several companies for bringing new drugs in the market provide good market opportunity for these companies in the near future.

Some of the key players in the global Klebsiella pneumoniae infection treatment market with drugs in pipeline include Arsanis Biosciences GmbH, Cubist Pharmaceuticals, Inc., Cantab Biopharmaceuticals Ltd., FOB Synthesis, Inc., Melinta Therapeutics, Inc., Northern Antibiotics Oy, Phico Therapeutics Ltd., Dainippon Sumitomo Pharma Co. Ltd., Procarta Biosystems Ltd., Pfizer, Inc., Soligenix, Inc., Rib-X Pharmaceuticals, Inc., Trana Discovery, Inc., and Tetraphase pharmaceuticals, Inc.

Enquiry for Discount on this Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2859

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Klebsiella Pneumoniae Infections Treatment Market with Current Trends Analysis, 2014 – 2020 here

News-ID: 1134893 • Views:

More Releases from Transparency Market Research

Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights for the USD 15.9 Bn Market 2022-2031
Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights f …
The global handheld marijuana vaporizer market has witnessed remarkable growth in recent years, attributed to the increasing acceptance of medicinal marijuana and the demand for convenient and discreet consumption methods. Valued at US$ 5 billion in 2021, the market is projected to surge at a CAGR of 13.4% to reach US$ 15.9 billion by 2031. This article delves into the factors driving this growth, the evolving market landscape, and the
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And Competitors
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And …
The COVID-19 pandemic has precipitated a remarkable surge in the demand for disinfectant products, with a notable emphasis on disinfectant wipes as an essential tool in maintaining hygiene and preventing the spread of pathogens. This research report delves into the multifaceted landscape of the disinfectant wipes market, elucidating key trends, drivers, and innovations shaping the industry. 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=70359 Key Players and Market Developments Key players
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Study
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Stud …
The global 𝐭𝐢𝐬𝐬𝐮𝐞 𝐛𝐚𝐧𝐤𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 reached a value of US$ 1,056.4 million in 2017 and is projected to nearly triple to US$ 2,903.3 million by 2026, with a robust Compound Annual Growth Rate (CAGR) of approximately 12.0% from 2018 to 2026. Factors such as increasing awareness about tissue donation, technological advancements, and a growing target patient population are anticipated to propel market growth during this period. Moreover, the market is expected
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
This report by Transparency Market Research, Inc. assesses the present state and future growth potential of the global 𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐜𝐥𝐨𝐬𝐮𝐫𝐞 𝐝𝐞𝐯𝐢𝐜𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭. It features a comprehensive executive summary, offering insights into various segments of the market. Additionally, the report provides detailed analysis and data on product, access type, application, end user, and regional segments within the global market. Vascular closure devices is estimated to reach a value of ~US$ 1 Bn

All 5 Releases


More Releases for Klebsiella

Klebsiella Infections Therapeutics- Pipeline Analysis 2018, Clinical Trials & Re …
Klebsiella infections include different types of infections like bloodstream infections; pneumonia; wound or surgical site infections; and meningitis, caused by the Klebsiella bacteria. The symptoms associated with these infections are high fevers, chills, cough, and shortness of breath. Download the sample report @ https://www.pharmaproff.com/request-sample/1065 Hospitalized patients undergoing treatment for other conditions may be susceptible to these infections. In healthcare settings, patients who require long courses of antibiotics, or are treated with
Klebsiella Pneumoniae Infections Market Symptoms, Consulting Services, Epidemiol …
Klebsiella Pneumoniae Infections Market Epidemiology outlays comprehensive Insight of the disease, historical & forecasted epidemiology as well as the market trends of Klebsiella Pneumoniae Infections Industry. The Report provides a detailed picture of the current treatment practices, emerging drugs, a market share of the individual therapies, current and forecasted market size of Klebsiella Pneumoniae Infections. The Klebsiella Pneumoniae Infections Market Report also covers current treatment practice/algorithm, market drivers, market barriers and
Klebsiella Testing Market to Record an Exponential CAGR by 2025
Klebsiella is a genus of gram-negative, rod-shaped bacteria. Klebsiella bacterial species can be found anywhere in nature such as, soil, water, plant, animal, insects and humans. Klebsiella normally lives inside human intestine but it does not cause any disease in intestine. Klebsiella cause a range of illness to the human body including, pneumonia, wound infection, surgical site infection, bloodstream infection, urinary tract infection and meningitis. Symptoms of klebsiella depends on
Klebsiella Testing Market: Advanced Technologies & Growth Opportunities in Globa …
Klebsiella is a genus of gram-negative, rod-shaped bacteria. Klebsiella bacterial species can be found anywhere in nature such as, soil, water, plant, animal, insects and humans. Klebsiella normally lives inside human intestine but it does not cause any disease in intestine. Klebsiella cause a range of illness to the human body including, pneumonia, wound infection, surgical site infection, bloodstream infection, urinary tract infection and meningitis. Symptoms of klebsiella depends on
Klebsiella Testing Market to Register Substantial Expansion by 2025
Klebsiella is a genus of gram-negative, rod-shaped bacteria. Klebsiella bacterial species can be found anywhere in nature such as, soil, water, plant, animal, insects and humans. Klebsiella normally lives inside human intestine but it does not cause any disease in intestine. Klebsiella cause a range of illness to the human body including, pneumonia, wound infection, surgical site infection, bloodstream infection, urinary tract infection and meningitis. Symptoms of klebsiella depends on
Research Focused on the Klebsiella Testing Market Forecast up to 2025
Klebsiella is a genus of gram-negative, rod-shaped bacteria. Klebsiella bacterial species can be found anywhere in nature such as, soil, water, plant, animal, insects and humans. Klebsiella normally lives inside human intestine but it does not cause any disease in intestine. Klebsiella cause a range of illness to the human body including, pneumonia, wound infection, surgical site infection, bloodstream infection, urinary tract infection and meningitis. Symptoms of klebsiella depends on